Lalezari 2011

Methods	Randomised clinical trial
Participants	64 participants Mean age: 50 years Country: USA Inclusion criteria: treatment‐naive adult participants with chronic hepatitis C.
Interventions	Experimental group: oral 200 mg, 400 mg, 800 mg of ACH‐1625 for 28 days. Control group: placebo. Co‐intervention: peg‐IFN‐α 2a/RBV.
Outcomes	Pharmacokinetics, HCV RNA, safety assessment.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The trial was described as placebo‐blinded but it was unclear how the blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The trial was described as placebo‐blinded but it was unclear how the blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	Unclear risk	Not described
Other bias	Low risk	The trial appeared to be free of other bias domains that could put it at risk of bias